Kalaris Therapeutics (KLRS) Other financing activities (2021 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Other financing activities of $74000.0 for Q1 2026, up 3600.0% quarter-over-quarter from $2000.0 in Q4 2024.
Kalaris Therapeutics (KLRS) Other financing activities (2021 - 2026) Analysis & Trends
Kalaris Therapeutics' Other financing activities history runs 5 years deep, the most recent figure standing at $74000.0 for Q1 2026.
- In Q1 2026, Other financing activities changed N/A year-over-year to $74000.0; the TTM figure through Mar 2026 stood at $69.9 million (changed N/A YoY), while the FY2025 annual figure was $8.0 million, up 266566.67% from the prior year.
- Other financing activities for Q1 2026 stood at $74000.0, up from $2000.0 in the prior quarter.
- The five-year high for Other financing activities was $69.9 million in Q4 2023, with the low at -$69.9 million in Q3 2023.
- The 4-year median for Other financing activities is $38000.0 (2024), against an average of $58000.0.
- The sharpest annual moves came in 2023 and 2024: Other financing activities soared 23822.6% in 2023, then sank 100.0% in 2024.
- Kalaris Therapeutics' Other financing activities stood at $292000.0 in 2022, then jumped by 23822.6% to $69.9 million in 2023, then tumbled by 100.0% to $2000.0 in 2024, then soared by 3600.0% to $74000.0 in 2026.
- Business Quant data shows KLRS's Other financing activities at $74000.0 in Q1 2026, $2000.0 in Q4 2024, and -$20000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10,000.00 |
| Jun 30, 2026 | 10,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | -20,000.00 |
| Sep 30, 2024 | -20,000.00 |
| Dec 31, 2023 | 69.85 Mn |
| Dec 31, 2023 | 69.85 Mn |
| Sep 30, 2023 | -69.85 Mn |
| Sep 30, 2023 | -69.85 Mn |
| Dec 31, 2022 | 292,000.00 |
| Dec 31, 2022 | 292,000.00 |
| Dec 31, 2021 | 65,000.00 |
| Dec 31, 2021 | 65,000.00 |